

Peer Review

Review of: "A Harmless Avian Vaccine Virus Could Be Developed into an Off-the-Shelf “Antibiotic” for Viruses"

Hany Akeel Al-hussaniy¹

1. University of Baghdad, Iraq

1. Over-Interpretation of Limited Clinical Evidence

The manuscript claims safety and efficacy across several viral diseases based on:

Small patient numbers

Case reports

Non-randomized observations

There is **no large randomized controlled clinical trial** supporting therapeutic efficacy.

→ This significantly weakens translational validity.

● 2. Reliance on Anecdotal or Personal Clinical Observations

Example:

Healing of herpes zoster infection in an author is described as evidence.

Such anecdotal evidence cannot support generalized clinical conclusions.

● 3. Lack of Balanced Risk Discussion

Potential concerns not sufficiently addressed:

Zoonotic mutation risks

Long-term immune dysregulation

Off-target inflammatory responses

4. Commentary Tone Occasionally Becomes Promotional

Statements suggesting the therapy could prevent millions of deaths or reduce pandemic costs appear speculative and not sufficiently supported by data.

5. Insufficient Critical Comparison with Existing Antiviral Strategies

The manuscript does not adequately compare SIT with:

Antiviral drugs

Monoclonal antibodies

mRNA vaccine platforms

Host-directed therapeutics

Declarations

Potential competing interests: No potential competing interests to declare.